New funding for MMV from AusAID
An Australian grant of $2.5 million to support the development of new antimalarial medicines has been welcomed as a significant step towards addressing malaria as resistance increases in the Asia Pacific region.
The grant to MMV is the first time AusAID has funded a global product development partnership to address one of the world’s most neglected diseases.
MMVs Chief Executive Officer, Dr David Reddy, said the funding provided by the Australian government to MMV reflects Australia’s growing commitment to developing antimalarial products to save lives and reduce global poverty.
“Global social and economic development hinge on addressing malaria, TB, HIV/AIDs and other neglected diseases,” Dr Reddy said.
“Australian scientists have made a substantial contribution to the development of new drugs and tools to address malaria, working in partnership with MMV and the international science community.”
“This funding will enable us to continue this work to address malaria in children and pregnant women, particularly in the Asia Pacific region where drug resistance is emerging.”
About 3.3 billion people - almost half of the world's population - are at risk of malaria. It kills around 655,000 people a year, 86% of them children under five. Papua New Guinea has around 1 million cases each year, where malaria is the no. 1 killer of children.1
MMV was created to address the lack of effective antimalarials by bringing public, private and philanthropic sector partners together to undertake research of new medicines. Its mission is to reduce the burden of malaria in disease-endemic countries.
MMV was established in 1999 as a not-for-profit Swiss foundation. MMV has contributed over $10 million to Australian-based malaria research since its inception 12 years ago.
See the announcement on the AusAID website.